The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | The role of CELMoDs in relapsed myeloma
Francesco Maura, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the potential role of cereblon E3 ligase modulators (CELMoDs), including mezigdomide, in the evolving treatment landscape of relapsed multiple myeloma. Dr Maura highlights their potential benefits for elderly and frail patients, particularly the convenience of oral administration, and explores their possible use in combination with or following BCMA-directed therapies. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
